Literature DB >> 32042626

Bladder cancer under staging: still unavoidable?

Angelo Naselli1, Andrea Guarneri2.   

Abstract

Entities:  

Year:  2019        PMID： 32042626      PMCID： PMC6989864          DOI： 10.21037/tau.2019.09.44

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  13 in total

1.  Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.

Authors:  Ronald Kool; José João Mansure; Wassim Kassouf
Journal:  Transl Androl Urol       Date:  2019-07

Review 2.  Clinical implications of molecular subtyping in bladder cancer.

Authors:  Uttam Satyal; Rahmat K Sikder; David McConkey; Elizabeth R Plimack; Philip H Abbosh
Journal:  Curr Opin Urol       Date:  2019-07       Impact factor: 2.309

3.  Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.

Authors:  Joshua I Warrick; Gottfrid Sjödahl; Matthew Kaag; Jay D Raman; Suzanne Merrill; Lauren Shuman; Guoli Chen; Vonn Walter; David J DeGraff
Journal:  Eur Urol       Date:  2018-09-25       Impact factor: 20.096

4.  Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Authors:  Angelo Naselli; Rodolfo Hurle; Stefano Paparella; Nicolò Maria Buffi; Giovanni Lughezzani; Giuliana Lista; Paolo Casale; Alberto Saita; Massimo Lazzeri; Giorgio Guazzoni
Journal:  Eur Urol Focus       Date:  2017-01-13

5.  Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.

Authors:  Polat Turker; Peter J Bostrom; Marcelo L Wroclawski; Bas van Rhijn; Hannes Kortekangas; Cynthia Kuk; Tuomas Mirtti; Neil E Fleshner; Michael A Jewett; Antonio Finelli; Theo Vander Kwast; Andy Evans; Joan Sweet; Matti Laato; Alexandre R Zlotta
Journal:  BJU Int       Date:  2012-02-09       Impact factor: 5.588

6.  A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.

Authors:  Anirban P Mitra; Eila C Skinner; Gus Miranda; Siamak Daneshmand
Journal:  BJU Int       Date:  2012-08-29       Impact factor: 5.588

7.  Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

Authors:  Zachary Klaassen; Ashish M Kamat; Wassim Kassouf; Paolo Gontero; Humberto Villavicencio; Joaquim Bellmunt; Bas W G van Rhijn; Arndt Hartmann; James W F Catto; Girish S Kulkarni
Journal:  Eur Urol       Date:  2018-07-13       Impact factor: 20.096

8.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

Authors:  J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal
Journal:  Eur Urol       Date:  2016-06-30       Impact factor: 20.096

9.  Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Authors:  Yair Lotan; Stephen A Boorjian; Jingbin Zhang; Trinity J Bivalacqua; Sima P Porten; Thomas Wheeler; Seth P Lerner; Ryan Hutchinson; Franto Francis; Elai Davicioni; Robert S Svatek; Chun-Liang Chen; Peter C Black; Ewan A Gibb
Journal:  Eur Urol       Date:  2019-05-12       Impact factor: 20.096

10.  Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Authors:  Roland Seiler; Ewan A Gibb; Natalie Q Wang; Htoo Zarni Oo; Hung-Ming Lam; Kim E van Kessel; Charlotte S Voskuilen; Brian Winters; Nicholas Erho; Mandeep M Takhar; James Douglas; Funda Vakar-Lopez; Simon J Crabb; Bas W G van Rhijn; Elisabeth E Fransen van de Putte; Ellen C Zwarthoff; George N Thalmann; Elai Davicioni; Joost L Boormans; Marc Dall'Era; Michiel S van der Heijden; Jonathan L Wright; Peter C Black
Journal:  Clin Cancer Res       Date:  2018-09-17       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.